Human papillomavirus type 16 E7 oncoprotein expressed in peripheral epithelium tolerizes E7-directed cytotoxic T-lymphocyte precursors restricted through human (and mouse) major histocompatibility complex class I alleles

Citation
T. Doan et al., Human papillomavirus type 16 E7 oncoprotein expressed in peripheral epithelium tolerizes E7-directed cytotoxic T-lymphocyte precursors restricted through human (and mouse) major histocompatibility complex class I alleles, J VIROLOGY, 73(7), 1999, pp. 6166-6170
Citations number
30
Categorie Soggetti
Microbiology
Journal title
JOURNAL OF VIROLOGY
ISSN journal
0022538X → ACNP
Volume
73
Issue
7
Year of publication
1999
Pages
6166 - 6170
Database
ISI
SICI code
0022-538X(199907)73:7<6166:HPT1EO>2.0.ZU;2-X
Abstract
Mice which coexpress human papillomavirus type 16 E7 and HLA A2.1 in periph eral squamous epithelium and thymic cortical epithelium are tolerant at the cytotoxic T-lymphocyte (CTL) level to E7 epitopes restricted through HLA A *0201 and H-2(b) (T. Doan, M. Chambers, M. Street, G. J. Fernando, If. Herd , P. Lambert, and R. Tindle, Virology 244:352-364, 1998), Here we used bone marrow-reconstituted radiation chimeras to distinguish whether E7-directed CTL tolerance was mediated peripherally by E7 expression in skin or centra lly by E7 expression in thymus. In chimeric mice expressing E7 in skin and reconstituted with E7-naive bone marrow and E7-naive thymus, CTL responses to vaccine-administered E7 epitopes mere not restored, i.e., the mice remai ned tolerant. In contrast, chimeric mice not expressing E7 in skin and reco nstituted with E7-naive bone marrow and E7-expressing thymus had fail E7-di rected CTL responses. These results demonstrate that E7 protein expression in peripheral squamous epithelium is sufficient to tolerize the E7-directed CTL precursor repertoire. The data have implications for E7-mediated tumor igenesis and for the development of E7-based immunotherapeutic strategies, since peripheral immunological tolerance of tumor-associated antigens may c reate a barrier to effective immunotherapy.